Related Experiment Video
Updated: Aug 9, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses
Hong Jiang1, Ramon Alemany, Candelaria Gomez-Manzano
1Department of Neuro-Oncology, Brain Tumor Center, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Oncolytic adenoviruses are being tested as potential therapies for human malignant tumors, including gliomas. Here we report for the first time that a mutation in the E1A gene results in low levels of E1A protein, conditioning the replication of mutant adenoviruses specifically to cancer cells. In this study, we compared the oncolytic potencies of three mutant adenoviruses encompassing deletions within the CR1 (Delta-39), CR2 (Delta-24) regions, or both regions (Delta-24/39) of the E1A protein. Delta-39 and Delta-24 induced a cytopathic effect with similar efficiency in glioma cells and a comparable capacity for replication. Importantly, the activity of Delta-39 was significantly attenuated compared to Delta-24 in proliferating normal human astrocytes. Direct analyses of the activation of E2F-1 promoter demonstrated the inability of Delta-39 to induce S-phase-related transcriptional activity in normal cells. Interestingly, E1A protein levels in cells infected with Delta-39 were remarkably downmodulated. Furthermore, protein stability studies revealed enhanced degradation of CR1 mutant E1A proteins, and inhibition of the proteasome activity resulted in the striking rescue of E1A levels. We conclude that the level of E1A protein is a critical determinant of oncolytic phenotype and we propose a completely novel strategy for the design and construction of conditionally replicative adenoviruses.
Insights
Mutant adenoviruses targeting cancer cells show promise. A specific E1A gene mutation limits replication to tumors, enhancing safety for glioma therapy and offering a novel oncolytic virus design strategy.
Area of Science:
- Virology
- Cancer Biology
- Gene Therapy
Background:
- Oncolytic adenoviruses are investigated for treating human cancers, including gliomas.
- Developing oncolytic viruses with enhanced tumor specificity is crucial for effective cancer therapy.
Purpose of the Study:
- To compare the oncolytic potencies of three mutant adenoviruses (Delta-39, Delta-24, Delta-24/39) with E1A gene mutations.
- To investigate the role of E1A protein levels in determining oncolytic adenovirus specificity and efficacy.
Main Methods:
- Generated and characterized three E1A-mutant adenoviruses (Delta-39, Delta-24, Delta-24/39).
- Assessed viral replication and cytopathic effects in glioma cells and normal human astrocytes.
- Analyzed E1A protein levels, E2F-1 promoter activity, and protein degradation pathways.
Main Results:
- Delta-39 and Delta-24 showed similar replication and cytopathic effects in glioma cells.
- Delta-39 exhibited significantly attenuated activity in normal astrocytes compared to Delta-24.
- Delta-39 failed to induce S-phase activity in normal cells and displayed downmodulated E1A protein levels due to enhanced degradation.
Conclusions:
- E1A protein level is a critical determinant of the oncolytic phenotype.
- The Delta-39 mutant offers a novel strategy for designing conditionally replicative adenoviruses with enhanced tumor specificity.
- Targeting E1A protein stability presents a new approach for oncolytic virus development.
